<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40972782</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3871</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Heart rhythm</Title><ISOAbbreviation>Heart Rhythm</ISOAbbreviation></Journal><ArticleTitle>Impact of Empagliflozin and Dapagliflozin on Sudden Cardiac Death: A Systematic Review and Meta-Analysis of Adjudicated Randomized Evidence.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1547-5271(25)02890-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hrthm.2025.09.023</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular outcomes in the spectrum of cardio-renal-metabolic syndrome. Albeit basic and translational evidence support a putative anti-arrhythmic role, at the clinical level, a lack of consensus has emerged across different studies, and the true impact on sudden cardiac death (SCD) risk remains unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the effect of empagliflozin and dapagliflozin on SCD in patients with type 2 diabetes, heart failure, or chronic kidney disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review and meta-analysis were conducted on randomized controlled trials. A total of 58,569 participants from 8 trials were included, with 30,565 patients treated with SGLT2 inhibitors and 28,104 controls assigned to placebo. The median follow-up period was 29 months. We performed pooled analysis, meta-regression, and subgroup analyses to explore the impact on SCD risk across different populations and treatment regimens.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The pooled analysis showed a reduced risk of SCD with SGLT2 inhibitors (OR: 0.82; 95% CI: 0.72-0.94; p = 0.0104), with negligible heterogeneity (&#x3c4;<sup>2</sup> = 0.0000; I<sup>2</sup> = 0.0%; Q = 3.17, p = 0.8687). Subgroup-specific estimates (age, follow-up duration, population, and SGLT2 inhibitor type) did not reach statistical significance. Meta-regression showed no significant moderation by mean age, study duration, or gender. No evidence of publication bias was detected.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Empagliflozin and dapagliflozin may reduce the relative risk of sudden cardiac death. These data expand the spectrum of cardiovascular benefits attributed to SGLT2 inhibition. Further trials specifically designed to address pre-adjudicated arrhythmic endpoints are warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matteucci</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy; Department of Experimental Medicine, Tor Vergata University, Rome, Italy. Electronic address: andrea.matteucci2@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandozi</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanni</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, Tor Vergata University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Marco Valerio</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, "Sapienza" University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sgarra</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Policlinic Hospital "F.Miulli', Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nesti</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiopulmonary Lab, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierucci</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, "Sapienza" University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Fazia</LastName><ForeName>Vincenzo Mirco</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavalle</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, "Sapienza" University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardi</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Santo Spirito Hospital, Casale Monferrato, 15033 Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colivicchi</LastName><ForeName>Furio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Rhythm</MedlineTA><NlmUniqueID>101200317</NlmUniqueID><ISSNLinking>1547-5271</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SGLT2 inhibitors</Keyword><Keyword MajorTopicYN="N">arrhythmias</Keyword><Keyword MajorTopicYN="N">dapagliflozin</Keyword><Keyword MajorTopicYN="N">empagliflozin</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">sudden cardiac death</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>19</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40972782</ArticleId><ArticleId IdType="doi">10.1016/j.hrthm.2025.09.023</ArticleId><ArticleId IdType="pii">S1547-5271(25)02890-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>